Liquidia (LQDA) Total Non-Current Liabilities (2019 - 2026)
Liquidia (LQDA) posted quarterly Total Non-Current Liabilities of $284.4 million for Q1 2026, up 67.12% year-over-year from $170.2 million in Q1 2025, and up 3.5% quarter-over-quarter from $274.8 million in Q4 2025.
Liquidia (LQDA) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Liquidia's Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $284.4 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 67.12% year-over-year to $284.4 million; the TTM figure through Mar 2026 stood at $284.4 million (up 67.12% YoY), while the FY2025 annual figure was $274.8 million, up 91.32% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $284.4 million, up from $274.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $284.4 million in Q1 2026, with the low at $30.5 million in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $93.3 million (2024), against an average of $119.4 million.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities advanced 28.22% in 2023, then surged 137.43% in 2024.
- Liquidia's Total Non-Current Liabilities stood at $32.2 million in 2022, then surged by 99.9% to $64.3 million in 2023, then jumped by 123.27% to $143.6 million in 2024, then surged by 91.32% to $274.8 million in 2025, then rose by 3.5% to $284.4 million in 2026.
- Business Quant data shows LQDA's Total Non-Current Liabilities at $284.4 million in Q1 2026, $274.8 million in Q4 2025, and $245.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Liquidia | 6.31 Bn | 6.03 Bn | 160.92 Mn | 318.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 318.26 Mn |
| Mar 31, 2026 | 284.41 Mn |
| Dec 31, 2025 | 274.80 Mn |
| Sep 30, 2025 | 245.65 Mn |
| Jun 30, 2025 | 234.25 Mn |
| Mar 31, 2025 | 170.18 Mn |
| Dec 31, 2024 | 143.64 Mn |
| Sep 30, 2024 | 135.17 Mn |
| Jun 30, 2024 | 107.71 Mn |
| Mar 31, 2024 | 93.30 Mn |
| Dec 31, 2023 | 64.33 Mn |
| Sep 30, 2023 | 56.93 Mn |
| Jun 30, 2023 | 54.25 Mn |
| Mar 31, 2023 | 40.67 Mn |
| Dec 31, 2022 | 32.18 Mn |
| Sep 30, 2022 | 30.97 Mn |
| Jun 30, 2022 | 30.46 Mn |
| Mar 31, 2022 | 31.72 Mn |
| Dec 31, 2021 | 22.32 Mn |
| Sep 30, 2021 | 22.26 Mn |